Haleon (LON:HLN) Reaches New 1-Year Low – Should You Sell?

Shares of Haleon plc (LON:HLN) hit a new 52-week low on Tuesday . The company traded as low as GBX 325 and last traded at GBX 327, with a volume of 137770469 shares traded. The stock had previously closed at GBX 327.10.

Wall Street Analysts Forecast Growth

HLN has been the topic of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft cut their price objective on Haleon from GBX 340 to GBX 335 and set a “buy” rating on the stock in a research report on Thursday, January 22nd. Berenberg Bank reiterated a “buy” rating and issued a GBX 512 price objective on shares of Haleon in a research report on Thursday, April 30th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a GBX 370 price objective on shares of Haleon in a research report on Thursday, April 30th. Finally, Jefferies Financial Group cut their price objective on Haleon from GBX 450 to GBX 400 and set a “buy” rating on the stock in a research report on Tuesday, May 5th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of GBX 398.67.

Haleon Trading Up 0.6%

The company has a market cap of £29.24 billion, a PE ratio of 17.78, a PEG ratio of 1.49 and a beta of 0.25. The company has a current ratio of 0.92, a quick ratio of 0.93 and a debt-to-equity ratio of 52.26. The stock has a 50 day moving average price of GBX 364.74 and a 200 day moving average price of GBX 370.45.

Haleon (LON:HLN) last announced its quarterly earnings data on Thursday, February 26th. The company reported GBX 18.60 earnings per share (EPS) for the quarter. Haleon had a return on equity of 6.43% and a net margin of 12.59%. Sell-side analysts predict that Haleon plc will post 19.5033282 EPS for the current fiscal year.

Insider Transactions at Haleon

In other Haleon news, insider Brian McNamara sold 704,974 shares of Haleon stock in a transaction on Monday, March 23rd. The stock was sold at an average price of GBX 368, for a total transaction of £2,594,304.32. Insiders own 0.01% of the company’s stock.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.